Tags

Type your tag names separated by a space and hit enter

Comparison of lipid and androgen levels after conjugated estrogen or depo-medroxyprogesterone acetate treatment in postmenopausal women.
Obstet Gynecol. 1985 Aug; 66(2):216-9.OG

Abstract

Thirty-five women who had undergone a natural or surgical menopause were randomized to receive either 0.625 mg of conjugated estrogen to be ingested for 25 days each month or 150 mg of depo-medroxyprogesterone acetate intramuscularly every three months. Plasma lipids were determined before and after one year of therapy. Serum androgens were measured before and after six months of therapy. Conjugated estrogens and depo-medroxyprogesterone acetate had similar effects on plasma lipids. Cholesterol was decreased (P less than .02 for conjugated estrogen therapy and P less than .01 for depo-medroxyprogesterone acetate therapy), as was low-density lipoprotein cholesterol (P less than .02 for conjugated estrogen and P less than .05 for depo-medroxyprogesterone acetate). Conjugated estrogens also significantly increased high-density lipoprotein cholesterol (P less than .02). High-density lipoprotein cholesterol levels were unchanged after depo-medroxyprogesterone acetate therapy. Serum androgens were generally unchanged after depo-medroxyprogesterone acetate or conjugated estrogen therapy. The data from this study suggest that long-term conjugated estrogen and depo-medroxyprogesterone acetate treatment have similar effects on lipid and androgen levels except that high-density lipoprotein cholesterol was not significantly increased by depo-medroxyprogesterone acetate.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

2991832

Citation

Barnes, R B., et al. "Comparison of Lipid and Androgen Levels After Conjugated Estrogen or Depo-medroxyprogesterone Acetate Treatment in Postmenopausal Women." Obstetrics and Gynecology, vol. 66, no. 2, 1985, pp. 216-9.
Barnes RB, Roy S, Lobo RA. Comparison of lipid and androgen levels after conjugated estrogen or depo-medroxyprogesterone acetate treatment in postmenopausal women. Obstet Gynecol. 1985;66(2):216-9.
Barnes, R. B., Roy, S., & Lobo, R. A. (1985). Comparison of lipid and androgen levels after conjugated estrogen or depo-medroxyprogesterone acetate treatment in postmenopausal women. Obstetrics and Gynecology, 66(2), 216-9.
Barnes RB, Roy S, Lobo RA. Comparison of Lipid and Androgen Levels After Conjugated Estrogen or Depo-medroxyprogesterone Acetate Treatment in Postmenopausal Women. Obstet Gynecol. 1985;66(2):216-9. PubMed PMID: 2991832.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of lipid and androgen levels after conjugated estrogen or depo-medroxyprogesterone acetate treatment in postmenopausal women. AU - Barnes,R B, AU - Roy,S, AU - Lobo,R A, PY - 1985/8/1/pubmed PY - 1985/8/1/medline PY - 1985/8/1/entrez SP - 216 EP - 9 JF - Obstetrics and gynecology JO - Obstet Gynecol VL - 66 IS - 2 N2 - Thirty-five women who had undergone a natural or surgical menopause were randomized to receive either 0.625 mg of conjugated estrogen to be ingested for 25 days each month or 150 mg of depo-medroxyprogesterone acetate intramuscularly every three months. Plasma lipids were determined before and after one year of therapy. Serum androgens were measured before and after six months of therapy. Conjugated estrogens and depo-medroxyprogesterone acetate had similar effects on plasma lipids. Cholesterol was decreased (P less than .02 for conjugated estrogen therapy and P less than .01 for depo-medroxyprogesterone acetate therapy), as was low-density lipoprotein cholesterol (P less than .02 for conjugated estrogen and P less than .05 for depo-medroxyprogesterone acetate). Conjugated estrogens also significantly increased high-density lipoprotein cholesterol (P less than .02). High-density lipoprotein cholesterol levels were unchanged after depo-medroxyprogesterone acetate therapy. Serum androgens were generally unchanged after depo-medroxyprogesterone acetate or conjugated estrogen therapy. The data from this study suggest that long-term conjugated estrogen and depo-medroxyprogesterone acetate treatment have similar effects on lipid and androgen levels except that high-density lipoprotein cholesterol was not significantly increased by depo-medroxyprogesterone acetate. SN - 0029-7844 UR - https://www.unboundmedicine.com/medline/citation/2991832/Comparison_of_lipid_and_androgen_levels_after_conjugated_estrogen_or_depo_medroxyprogesterone_acetate_treatment_in_postmenopausal_women_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=2991832.ui DB - PRIME DP - Unbound Medicine ER -